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Here we provide data from a head-to-head comparison study
using four biosensor platforms: GE Healthcare's Biacore T100, Bio-
Rad's ProteOn XPR36, ForteBio's Octet RED384, and Wasatch
Microﬂuidics's IBIS MX96. We used these instruments to analyze
the binding interactions of a panel of ten high-afﬁnity monoclonal
antibodies with their antigen, human proprotein convertase sub-
tilisin kexin type 9 (PCSK9). For each instrument, binding curves
obtained at multiple densities of surface antibodies were ﬁt to the
1:1 Langmuir kinetic model, and the association and dissociation
rate constants and corresponding afﬁnity constants were calcu-
lated. The data supplied in this article accompany the research
article entitled, “Comparison of biosensor platforms in the eva-
luation of high afﬁnity antibody–antigen binding kinetics” (Yang
et al., 2016) [1], which further discusses the strengths and weak-
nesses of each biosensor platform with an emphasis on data con-
sistency, comparability, and operational efﬁciency.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.ab.2016.06.024
odulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharma-
06877-0368, United States.
-ingelheim.com (R. Kroe-Barrett).
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acquiredGE Healthcare's Biacore T100, Bio-Rad's ProteOn XPR36, ForteBio's Octet
RED384, and Wasatch Microﬂuidics's IBIS MX96ata format Analyzed
xperimental
factorsAntibodies were captured or immobilized onto the sensor surface at multiple
densities, and the antigen (hu PCSK9) was ﬂowed over the antibody surface at
titrating concentrations.xperimental
featuresCharacterization of kinetic rate and equilibrium binding constants obtained from
binding curves (10-min or 500-s association period and 45-min dissociation
period) using the 1:1 Langmuir kinetic modelata source
locationDepartment of Immune Modulation and Biotherapeutics Discovery, Boehringer
Ingelheim Pharmaceuticals, Inc., Ridgeﬁeld, CT 06877ata accessibility Data are within this articleD
Value of the data
 The data enable the head-to-head comparison of four instruments’ performance regarding data
consistency and comparability.
 The data can help new biosensor users determine the best instrument for their research purposes
and maximize the value of their investment.
 The data provide additional insights for current biosensor users regarding the systematic factors
that inﬂuence data reliability.1. Data
Table 1 contains the calculated antibody surface binding activity for the antigen obtained using
three instruments (ProteOn XPR36, Biacore T100, and Octet RED384), and Tables 2 and 3 contain the
association (ka), dissociation (kd), and equilibrium (KD) binding constants obtained by applying the
binding curves recorded using the same three instruments and the IBIS MX96. Table 4 contains the
ﬁnal kinetic rates and binding constants obtained from global analysis of the binding curves from
multiple antibody-coated surfaces, and Table 5 contains the ratio of the instrumental limits provided
by the manufacturers to the experimentally determined rate constants.2. Experimental design, materials and methods
2.1. Proteins and antibodies
To prepare the antigen, suspended HEK293-6E cells were transfected with a plasmid encoding C-
terminally 6-His-tagged human PCSK9, using the TransIT-PRO system (Mirus Bio LLC). After a 4-day
incubation, the medium was harvested, and the 6-His-tagged PCSK9 was puriﬁed using a Ni-NTA His-
Bind Superﬂow column (Novagen), according to the manufacturer's instructions.
To prepare 20 different monoclonal antibodies (mAbs) against human PCSK9, CHO cells were
transfected with plasmid DNAs containing heavy chain and light chain cassettes, using Freestyle CHO
Expression Medium containing 8 mM Glutamax (Invitrogen). After a 7-day incubation, the medium
was harvested, and antibodies were puriﬁed using an ÄKTA afﬁnity chromatography system with
MabSelect Sure resin (GE Healthcare), by standard procedures [2]. The puriﬁed mAbs were
Table 1
Antibody binding activities for human PCSK9. The slope and R2 values were obtained from the linear regression ﬁt of the
experimental Rmax vs. RL correlation curves (see Fig. 4 in Ref. [1]). The % activity was the ratio of the experimentally obtained
slope to the theoretical Rmax/RL value, as deﬁned by the known molar mass of the antigen and antibody (see Materials and
methods).
mAb ID ProteOn XPR36 Biacore T100 Octet RED384
Slope R2 % Activity Slope R2 % Activity Slope R2 % Activity
mAb 1 0.6859 0.9986 71% 0.7938 0.9983 82% 0.6923 0.9985 71%
mAb 2 0.7368 0.9963 76% 0.7463 0.9996 77% 0.9692 0.9881 100%
mAb 3 0.7079 0.9994 73% 0.8399 0.9989 87% 0.4684 0.9763 48%
mAb 4 0.5793 0.9994 60% 0.6009 1.0000 62% 0.6000 0.9838 62%
mAb 5 0.6035 0.9999 62% 0.7056 0.9988 73% 0.6333 0.9774 65%
mAb 6 0.5595 1.0000 58% 0.9440 0.9969 97% 0.7643 0.9997 79%
mAb 7 0.7495 0.9787 77% 0.7653 0.9998 79% 1.0000 1.0000 103%
mAb 8 0.5097 0.9897 53% 0.8446 0.9999 87% 0.5214 0.9844 54%
mAb 9 0.4363 0.9743 45% 0.8488 1.0000 88% 0.8769 0.9918 90%
mAb 10 0.5653 1.0000 58% 0.7663 0.9999 79% 0.9538 0.9727 98%
Mean 0.613 0.994 63% 0.786 0.999 81% 0.748 0.987 77%
St dev 0.104 0.010 0.107 0.093 0.001 0.096 0.194 0.010 0.200
% CV 17% 0.97% 17% 12% 0.10% 12% 26% 1.02% 26%
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adsorption at 280 nm, using a NanoDrop™ 8000 Spectrophotometer (Thermo Fischer Scientiﬁc) and
an extinction coefﬁcient of 1.36 [2]. The antibodies were determined to be 495% monomers by size
exclusion ultra-performance liquid chromatography (UPLC) (ACQUITY, Waters Corporation).
2.2. Instruments and reagents
Four biosensors were used for the binding experiments: the Biacore T100 [3], ProteOn XPR36 [4],
Octet RED384 [5], and IBIS MX96 [6]. The Biacore T100, equipped with CM5 sensor chips, was pur-
chased from GE Healthcare (Piscataway, NJ, USA); the ProteOn XPR36, equipped with a GLM sensor
chip, from Bio-Rad (Hercules, CA, USA); the Octet RED384, equipped with AHC (anti-Human IgG Fc
capture) biosensor tips, from ForteBio (Menlo Park, CA, USA); and the IBIS MX96, supplied with a CFM
printer and SensEye COOH-G chip, fromWasatch Microﬂuidics (Salt Lake City, UT, USA). Recombinant
protein A/G was from Thermo Fischer Scientiﬁc (catalog #21186). To couple the protein A/G to the
biosensor surface, an amine coupling kit containing 10 mM sodium acetate (pH 4.5), 200 mM 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 50 mM N-hydroxysuccinimide (NHS),
and 1 M ethanolamine-HCl (pH 8.5) (GE Healthcare, product #BR1000050) or the ProteOn amine
coupling kit, containing 400 mM EDC, 100 mM N-hydroxysulfosuccinimide (sulfo-NHS), and 1 M
ethanolamine-HCl (pH 8.5) (Bio-Rad, catalog #1762410) was used. Various regeneration solutions
were tested, including 4 M MgCl2, 10 mM glycine-HCl (pH 2.5, pH 2.0, and pH 1.5) (GE Healthcare),
and 0.85% phosphoric acid (Bio-Rad) stock diluted 1/500 (v/v) in water.
2.3. Biacore T100 kinetic measurements
Protein A/G was immobilized onto the four individual ﬂow cells in the CM5 sensor chip by a
standard coupling protocol. First, the carboxyl groups on the sensor surface were activated by
injecting 200 mM EDC/50 mM NHS. Next, protein A/G (30 mg/ml in sodium acetate [pH 4.5]) was
injected over the activated surface, to which it became covalently attached by its primary amines. The
excess reactive esters were then blocked with 1 M ethanolamine. Each step was performed with a
7-min injection and a 5 ml/min ﬂow rate. The ﬂow rate was increased to 10 ml/min for the subsequent
antibody-capturing step,. Each mAb, prepared at 0.063 mg/ml in HBS-EP running buffer (10 mM
HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA, and 0.005% v/v polysorbate P20) was serially injected onto
ﬂow cells 2, 3, and 4 for 220 s, 110 s, and 55 s, respectively. Flow cell 1 was left empty to provide a
Table 2
Kinetic rates and equilibrium binding constants obtained by ﬁtting the data generated for individual antibody surfaces in the Biacore T100, ProteOn XPR36, and Octet RED384 to the 1:1
interaction model (see Figs. 7–9 in Ref. [1]).
mAb ID Surface density Biacore T100 ProteOn XPR36 Octet RED384
ka (M1 s1) kd (s1) KD (M) Chi2 (RU) ka (M1 s1) kd (s1) KD (M) Chi2 (RU) ka (M1 s1) kd (s1) KD (M) X2 (nm)
mAb 1 High 18.6105 3.03105 0.016 0.1 21.7105 4.88105 0.023 3.3 3.63105 1.59105 0.044 2.1
Medium 19.4105 3.16105 0.016 0.1 21.2105 5.42105 0.026 3.8 4.52105 1.16105 0.026 1.8
Low 18.6105 3.03105 0.016 0.1 23.3105 6.38105 0.027 2.8 5.30105 1.28105 0.024 2.3
mAb 2 High 1.82105 2.17105 0.120 1.1 1.23105 3.24105 0.263 4.0 1.35105 0.63105 0.047 2.0
Medium 1.87105 2.85105 0.152 0.4 1.20105 3.56105 0.297 4.0 1.46105 0.58105 0.040 2.2
Low 2.00105 3.73105 0.187 0.1 1.29105 4.71105 0.365 3.4 1.64105 0.12105 0.007 1.4
mAb 3 High 21.3105 25.1105 0.118 1.5 20.1105 35.2105 0.175 4.9 3.67105 13.1105 0.357 4.5
Medium 19.3105 23.8105 0.123 0.5 20.0105 35.1105 0.176 3.6 4.29105 12.6105 0.294 4.5
Low 19.6105 22.7105 0.116 0.4 20.1105 41.0105 0.204 2.8 5.86105 16.4105 0.279 4.3
mAb 4 High 7.17105 24.6105 0.344 9.8 4.81105 23.9105 0.497 11.5 3.22105 12.6105 0.391 7.2
Medium 7.76105 25.2105 0.325 2.9 4.68105 23.2105 0.496 9.2 3.54105 12.0105 0.338 6.5
Low 6.80105 22.5105 0.331 0.8 5.08105 22.1105 0.435 5.0 4.52105 12.4105 0.275 6.2
mAb 5 High 0.73105 3.89105 0.535 0.8 0.61105 6.75105 1.110 3.7 0.80105 1.61105 0.202 1.2
Medium 0.71105 3.70105 0.523 0.3 0.58105 7.29105 1.260 3.1 0.86105 0.76105 0.088 1.4
Low 0.87105 4.25105 0.489 0.1 0.59105 11.6105 1.670 3.0 0.91105 0.91105 0.099 1.1
mAb 6 High 2.23105 7.26105 0.326 0.8 71.2105 6.48105 0.910 4.8 1.79105 1.68105 0.094 1.3
Medium 2.29105 7.16105 0.312 0.3 70.9105 6.27105 0.884 3.4 1.88105 3.87105 0.206 1.4
Low 2.46105 7.61105 0.309 0.2 79.8105 7.03105 0.881 3.3 1.89105 3.03105 0.160 2.0
mAb 7 High 1.72105 14.3105 0.828 1.3 1.04105 14.7105 1.410 4.1 1.58105 12.1105 0.766 1.6
Medium 1.83105 14.1105 0.770 0.4 1.04105 14.9105 1.430 3.5 1.76105 11.5105 0.652 1.9
Low 1.94105 14.2105 0.730 0.1 1.25105 23.4105 1.870 3.6 1.73105 13.3105 0.768 1.5
mAb 8 High 4.43105 19.7105 0.444 6.4 7.57105 34.1105 0.450 6.3 3.24105 4.29105 0.132 2.0
Medium 4.98105 19.6105 0.394 1.7 7.05105 35.2105 0.499 4.1 3.62105 5.23105 0.144 2.4
Low 4.90105 18.2105 0.371 0.5 6.69105 42.3105 0.632 3.2 4.61105 7.58105 0.164 2.0
mAb 9 High 6.37105 5.78105 0.091 1.8 2.20105 8.43105 0.383 4.0 3.00105 1.08105 0.036 2.0
Medium 6.87105 5.93105 0.086 0.5 2.17105 9.21105 0.424 3.3 3.45105 0.36105 0.010 2.9
Low 7.03105 6.25105 0.089 0.1 2.44105 11.2105 0.459 2.9 4.73105 0.62105 0.013 2.5
mAb 10 High 1.51105 9.40105 0.624 1.0 1.04105 14.7105 1.410 4.5 1.63105 4.09105 0.251 2.1
Medium 1.59105 9.68105 0.608 0.4 1.04105 14.9105 1.430 3.9 1.66105 3.77105 0.227 2.0
Low 1.66105 9.97105 0.602 0.1 1.25105 23.4105 1.870 3.5 1.96105 5.16105 0.263 1.3
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Table 3
Kinetic rates and equilibrium binding constants obtained by ﬁtting data generated for individual antibody surfaces in the IBIS
MX96 to the 1:1 interaction model (see Fig. 10 in Ref. [1]).
mAb ID Array spot IBIS MX96 (amine-coupled) IBIS MX96 (Fc-captured)
ka (M1 s1) kd (s1) KD (M) Chi2 (RU) ka (M1 s1) kd (s1) KD (M) Chi2 (RU)
mAb 1 1 – – – – – – – –
13 6.37105 12.3105 0.193 2.1 3.82105 3.12105 0.082 5.3
25 7.51105 18.0105 0.239 0.9 – – – –
37 6.38105 10.3105 0.161 1.1 4.97105 3.79105 0.076 5.0
49 – – – – – – –
61 10.0105 9.03105 0.090 2.2 4.87105 2.92105 0.060 3.0
73 15.3105 9.79105 0.064 1.1 6.56105 3.65105 0.056 2.9
85 – – – – – – – –
mAb 2 2 – – – – 1.26105 0.10105 0.008 3.4
14 – – – – 1.24105 0.10105 0.008 3.6
26 – – – – – – – –
38 – – – – 3.11105 0.10105 0.003 4.3
50 1.14105 0.55105 0.048 1.3 1.63105 0.10105 0.006 0.9
62 1.39105 0.37105 0.027 1.6 1.59105 0.10105 0.006 1.8
74 1.24105 0.42105 0.034 1.1 1.57105 0.10105 0.006 1.7
86 – – – – 2.09105 0.10105 0.005 1.2
mAb 3 3 7.25105 33.3105 0.460 3.1 3.44105 21.4105 0.621 11.6
15 5.70105 41.4105 0.727 3.0 3.14105 21.1105 0.671 13.5
27 5.85105 54.6105 0.933 1.4 6.96105 31.9105 0.458 6.8
39 7.14105 39.2105 0.549 1.1 – – – –
51 9.21105 36.0105 0.391 3.0 4.33105 20.5105 0.474 11.4
63 – – – – 4.09105 21.7105 0.531 9.2
75 – – – – 6.47105 27.9105 0.432 5.2
87 – – – – 14.0105 37.9105 0.283 1.1
mAb 4 4 2.05105 34.7105 1.700 4.7 1.53105 9.19105 0.599 10.2
16 2.02105 39.6105 1.960 3.5 1.39105 8.66105 0.621 8.8
28 – – – – – – – –
40 – – – – – – – –
52 2.56105 35.0105 1.370 8.7 1.42105 8.85105 0.624 9.6
64 2.93105 37.4105 1.280 4.4 1.62105 8.88105 0.549 10.6
76 2.38105 44.2105 1.850 3.2 1.49105 12.0105 0.804 2.0
88 – – – – – – – –
mAb 5 5 0.44105 4.00105 0.901 3.3 0.31105 1.74105 0.570 2.6
17 0.37105 5.62105 1.510 2.6 0.33105 1.51105 0.453 3.5
29 – – – – – – – –
41 – – – – 0.39105 1.15105 0.292 2.8
53 0.38105 3.08105 0.819 3.0 0.33105 2.05105 0.618 2.9
65 – – – – 0.34105 2.20105 0.656 1.9
77 – – – – 0.42105 1.76105 0.416 1.0
89 – – – – 0.56105 2.09105 0.375 1.0
mAb 6 7 0.84105 14.2105 1.690 2.6 – – – –
19 0.63105 16.4105 2.600 3.2 0.35105 6.21105 1.760 5.0
31 0.79105 13.7105 1.740 3.6 – – – –
43 – – – – – – – –
55 0.85105 13.5105 1.600 2.6 0.36105 5.42105 1.490 3.3
67 1.06105 13.2105 1.240 1.4 0.39105 5.46105 1.390 3.1
79 1.00105 9.91105 0.989 0.9 0.41105 5.57105 1.370 2.0
91 – – – – 0.55105 13.8105 2.520 1.1
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Table 3 (continued )
mAb ID Array spot IBIS MX96 (amine-coupled) IBIS MX96 (Fc-captured)
ka (M1 s1) kd (s1) KD (M) Chi2 (RU) ka (M1 s1) kd (s1) KD (M) Chi2 (RU)
mAb 7 8 1.20105 22.2105 1.840 0.9 0.59105 18.7105 3.170 4.1
20 – – – – 0.59105 15.7105 2.670 6.1
32 – – – – – – – –
44 – – – – 0.28105 16.4105 5.800 6.0
56 1.41105 25.6105 1.820 1.8 0.53105 17.2105 3.280 4.5
68 1.13105 28.9105 2.560 2.3 0.62105 16.3105 2.630 5.4
80 1.52105 24.8105 1.630 3.1 0.66105 17.4105 2.680 2.0
92 – – – – – – – –
mAb 8 9 3.68105 23.5105 0.638 6.1 1.12105 22.8105 2.030 8.6
21 3.70105 25.1105 0.678 5.2 1.32105 22.4105 1.700 6.6
33 3.92105 32.0105 0.815 3.1 1.03105 22.7105 2.200 5.5
45 3.20105 36.6105 1.140 2.1 – – – –
57 3.78105 25.0105 0.662 6.5 1.10105 22.1105 2.000 7.2
69 3.99105 31.4105 0.784 4.2 1.20105 22.6105 1.880 6.5
81 3.46105 33.9105 0.978 5.1 1.41105 25.5105 1.820 4.8
93 – – – – – – – –
mAb 9 10 4.72105 11.4105 0.242 4.1 2.08105 5.61105 0.270 5.3
22 5.36105 13.0105 0.242 4.0 2.76105 8.05105 0.292 2.7
34 – – – – – – – –
46 8.34105 12.9105 0.155 1.8 – – – –
58 7.36105 9.78105 0.133 2.0 1.96105 6.92105 0.352 6.5
70 6.05105 11.2105 0.186 1.9 1.99105 6.68105 0.335 5.4
82 – – – – 2.45105 7.19105 0.294 3.9
94 – – – – – – – –
mAb 10 11 0.80105 18.2105 2.270 2.6 0.37105 8.18105 2.210 4.3
23 0.93105 21.0105 2.270 1.8 0.30105 6.81105 2.290 5.7
35 – – – – – – – –
47 – – – – – – – –
59 1.32105 16.3105 1.240 2.8 0.51105 9.88105 1.950 4.7
71 0.95105 18.5105 1.950 2.2 0.55105 9.67105 1.760 4.9
83 1.34105 14.4105 1.080 1.7 0.58105 10.6105 1.820 2.8
95 0.94105 15.6105 1.660 1.1 – – – –
D. Yang et al. / Data in Brief 8 (2016) 1173–11831178reference surface. To measure the binding kinetics, human PCSK9 (100–0.39 nM in 2-fold serial
dilutions), and a buffer blank for baseline subtraction were sequentially injected, with a regeneration
step inserted between each cycle. The protein A/G surface was regenerated with two 18-s pulses of
glycine (pH 1.5) at 50 ml/min. The binding interactions were monitored over a 10-min association
period and a 45-min dissociation period (running buffer only), at 30 ml/min.
2.4. ProteOn XPR36 kinetic measurements
To immobilize protein A/G onto the GLM sensor chip imprinted with 6 crisscrossing ﬂow channels,
a procedure similar to the above-described coupling method was used, except that 100 mM sulfo-
NHS/400 mM EDC was used in the activation step. The activation, immobilization, and deactivation
steps were each performed for 5 min with 6 parallel injections in the horizontal direction at 30 ml/
min. The protein A/G-bound surfaces were then conditioned with three 18-s pulses of glycine (pH 1.5)
at 100 ml/min in the horizontal and vertical directions. Two different mAbs, each prepared at 0.25 mg/
ml, 0.125 mg/ml, and 0.063 mg/ml in PBS-T-EDTA running buffer (PBS [pH 7.4], 0.005% Tween-20, and
3 mM EDTA) were then injected in parallel in the vertical direction for 160 s at 25 ml/min. One mAb
Table 4
Kinetic rates and equilibrium binding constants of 10 mAbs obtained by ﬁtting global binding curve data from multiple surfaces to the 1:1 interaction model.
mAb
ID
Biacore T100 ProteOn XPR36 Octet RED384 IBIS MX96 (Fc -captured) IBIS MX96 (amine-coupled)
ka
(M1 s1)
kd (s1) KD
(M)
ka
(M1 s1)
kd (s1) KD
(M)
ka
(M1 s1)
kd (s1) KD
(M)
ka
(M1 s1)
kd (s1) KD
(M)
ka
(M1 s1)
kd (s1) KD
(M)
mAb 1 18.1105 3.05105 0.017 21.7105 5.14105 0.024 4.31105 0.99105 0.023 5.05105 3.37105 0.067 9.11105 11.9105 0.131
mAb 2 1.84105 2.42105 0.131 1.23105 3.44105 0.280 1.56105 0.10105 0.006 1.78105 0.10105 0.006 1.26105 0.45105 0.036
mAb 3 20.8105 24.7105 0.119 20.0105 35.6105 0.178 4.54105 12.7105 0.279 4.74105 24.1105 0.508 7.03105 40.9105 0.582
mAb 4 5.36105 21.3105 0.398 4.79105 23.5105 0.491 4.00105 8.46105 0.211 1.49105 8.90105 0.597 2.39105 38.2105 1.600
mAb 5 0.73105 3.86105 0.530 0.60105 7.04105 1.170 0.84105 0.50105 0.059 0.38105 1.79105 0.471 0.38105 4.11105 1.080
mAb 6 2.25105 7.25105 0.322 0.72105 6.44105 0.894 1.76105 3.21105 0.182 0.38105 5.67105 1.490 0.86105 13.5105 1.570
mAb 7 1.76105 14.2105 0.807 1.04105 15.0105 1.440 1.80105 10.2105 0.567 0.54105 17.0105 3.150 1.32105 25.4105 1.920
mAb 8 4.56105 19.4105 0.425 7.34105 35.0105 0.477 3.31105 7.02105 0.212 1.20105 23.0105 1.920 3.68105 29.4105 0.800
mAb 9 6.52105 5.84105 0.090 2.20105 8.82105 0.401 3.69105 0.10105 0.003 2.25105 6.89105 0.306 3.18105 11.7105 0.368
mAb
10
1.53105 9.50105 0.621 1.22105 23.1105 1.890 1.73105 3.72105 0.215 0.46105 9.03105 1.960 0.52105 17.3105 3.320
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Table 5
Ratio of the recommended instrumental working limits to the analyzed kinetic rate constants.
mAb ID Biacore T100a ProteOn XPR36b Octet RED384c IBIS MX96d IBIS MX96d
(Fc -captured) (amine-coupled)
ka kd ka kd ka kd ka kd ka kd
mAb 1 5.5 3.1 1.4 51.4 23.2 10.0 5.5 59.5 9.9 16.9
mAb 2 54.3 2.4 24.4 34.4 64.1 1.0 39.7 2.2 28.1 0.5
mAb 3 4.8 24.7 1.5 356.0 22.0 127.0 7.1 204.5 10.5 120.5
mAb 4 18.7 21.3 6.3 235.0 25.0 84.6 20.9 191.0 33.6 44.5
mAb 5 137.4 3.9 49.9 70.4 119.0 5.0 131.9 20.6 130.5 9.0
mAb 6 44.4 7.3 41.9 64.4 56.8 32.1 58.1 67.5 131.9 28.4
mAb 7 56.8 14.2 28.8 150.0 55.6 102.0 37.9 127.0 91.9 85.0
mAb 8 21.9 19.6 4.1 350.0 30.2 70.2 13.6 148.0 41.7 115.0
mAb 9 15.3 5.8 13.6 88.2 27.1 1.0 7.9 58.5 22.2 34.5
mAb 10 65.4 9.5 24.6 231.0 57.8 37.2 48.1 86.5 108.2 45.2
a Uppermost ka limit (M1 s1): 1107; lowest kd limit (s1): 1105 [7].
b Uppermost ka limit (M1 s1): 3106; lowest kd limit (s1): 1106 [8].
c Uppermost ka limit (M1 s1): 1107; lowest kd limit (s1): 1106 [9].
d Uppermost ka limit (M1 s1): 5106; lowest kd limit (s1): 2106 [10].
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was then switched, and a buffer blank was injected for 60 s. The antigen-binding kinetics of the mAbs
in the six samples was measured by simultaneously injecting ﬁve human PCSK9 samples at different
concentrations in running buffer and a buffer blank. Three different series of human PCSK9 con-
centration ranges (100–6.25 nM, 25–1.56 nM, and 5–0.313 nM), prepared by 2-fold serial dilution,
were used. The binding was monitored over a 10-min association period and a 45-min dissociation
period (running buffer only) at 40 ml/min. After each binding cycle, the protein A/G surface was
regenerated with two 18-s pulses of glycine (pH 1.5) at 100 ml/min in the horizontal and vertical
directions.
2.5. Octet RED384 kinetic measurements
Each mAb was prepared at 20 mg/ml, 10 mg/ml, and 5 mg/ml in 1KB running buffer (PBS pH [7.4],
0.02% Tween-20, 0.1% albumin, and 0.05% sodium azide) and dispensed into a 384-well tilted-bottom
microplate (90 ml per well). Eight vertical wells were used for each concentration. A second 384-well
microplate contained human PCSK9 at 7 different concentrations (100–1.56 nM, in 2-fold serial
dilutions), the glycine [pH 1.5] regeneration solution, and 1KB buffer for baseline stabilization. Both
plates were agitated at 1000 rpm during the entire experiment. Sixteen AHC (anti-human Fc capture)
sensor tips were used for a group of 2 mAbs (8 sensors each) per binding cycle. Before the binding
measurements, the sensor tips were pre-hydrated in 1KB for 5 min, followed by 3 pre-conditioning
cycles consisting of 15-s dips in glycine (pH 1.5) alternating with 15-s dips in 1KB. The sensor tips
were then transferred to the mAb-containing wells for a 200-s loading step. After a 60-s baseline dip
in 1KB, the binding kinetics were measured by dipping the mAb-coated sensors into the wells
containing human PCSK9 at various concentrations. The binding interactions were monitored over a
500-s association period, followed by a 30-min dissociation period, in which the sensors were dipped
into new wells containing 1KB buffer only. The AHC sensor tips were regenerated with two 18-s
dips in glycine (pH 1.5) between each binding cycle.
2.6. IBIS MX96 kinetic measurements
2.6.1. Multi-cycle kinetics with amine-coupled antibody arrays
For multi-array printing with the CFM, two 96-well microplates were prepared. The sample source
plate contained 8 vertical wells of each mAb in sodium acetate (pH 5.0) at concentrations ranging
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pared 400 mM EDC/100 mM sulfo-NHS. The COOH-G SensEye chip in the CFM was primed with
sodium acetate (pH 5.0) running buffer, the sensor surface was then activated with the EDC/sulfo-NHS
for 5 min, and the mAbs were then directly immobilized onto the activated surface. In the immobi-
lization step, the mAb samples in the top half of the source plate were delivered to the sensor using
48 micro-channels, by which the mAbs were cycled across the activated surface bidirectionally for
10 min. The procedure was repeated for the remaining mAb samples in the bottom half of the source
plate, generating a 108 array of mAb spots on the sensor surface. Two vertical columns of buffer-
containing wells served as reference samples. The printed sensor chip was then inserted into the
MX96 instrument and primed with the system running buffer (PBS [pH 7.4], 0.01% Tween-20). The
surfaces were then quenched with 1 M ethanolamine for 5 min. For the binding measurements,
human PCSK9 at 9 different concentrations (0.39–100 nM in 2-fold serial dilutions) in running buffer
was cycled across the mAb array surface. Each sequentially injected sample was monitored for a
10-min association period followed by a 45-min dissociation period, at a ﬂow rate of 40 ml/min. The
amine-coupled mAb surfaces were regenerated between each binding cycle with glycine (pH 2.0 or
pH 2.5). These regeneration conditions were determined in a preliminary experiment.
2.6.2. Single-cycle kinetics with Fc-captured antibody arrays
A SensEye COOH-G chip was inserted into the MX96 instrument and primed with sodium acetate
(pH 5.0). The sensor surface was activated by injecting 400 mM EDC/100 mM sulfo-NHS for 5 min,
and then 50 mg/ml protein A/G in sodium acetate (pH 5.0) was cycled bidirectionally across the
activated surface for 5 min. The sensor chip with the immobilized protein A/G surface was then
removed from the MX96 and inserted into the CFM printer, which had been loaded with a 96-well
mAb source plate. The same plate layout and mAb concentrations described above for the amine-
coupled antibody array were used, but the mAbs were prepared in a system running buffer consisting
of 0.01% Tween-20 in PBS. The mAb samples were captured by cycling them across the protein A/G
surface for 10 min, then the sensor chip was inserted back into the MX96 instrument and primed
with the system running buffer. The binding was measured by cycling human PCSK9 prepared at
7 different concentrations (1.56–100 nM in 2-fold serial dilutions) in the system running buffer. The
cycling of each sequentially injected sample was monitored as described in the previous section. No
regeneration was performed between sample injections.
2.7. Data analysis
2.7.1. Data processing and curve ﬁtting
The binding sensorgrams were all collected at 25 °C. Before the curve-ﬁtting analysis, the acquired
data were processed as follows. The Biacore T100 data were double-referenced using reference ﬂow
cell 1 and the subtraction of a preceding buffer blank with BiaEvaluation (v.4.1), and the ProteOn
XPR36 data were double-referenced using channel inter-spots and subtraction of a parallel in-line
buffer blank by the integrated ProteOn Manager software (v.3.1.0.6). The Octet RED384 data were
referenced by subtracting a parallel buffer blank, and the baseline was aligned with the y-axis and
smoothed by a Savitzky–Golay ﬁlter in the data analysis software (v.9.0.0.4). The IBIS MX96 data
underwent inter-spot reference subtraction, followed by y-axis alignment using the IBIS SPRint
software (v.6.15.2.1). The calibrated data were then exported to Scrubber (v.2.0c) for cropping,
aligning, and buffer referencing.
The processed binding curves from the four instruments were all ﬁtted to the Langmuir model for
a 1:1 binding stoichiometry. In the Biacore T100, “single mode” was used for the ﬁtting of data from
individual mAb surfaces, and “batch mode” with “local” Rmax was used for the global ﬁtting of data
from multiple mAb surfaces. In the ProteOn XPR36, the “grouped” and “global” modes and the “local”
Rmax were used for the ﬁtting of data from single vs. multiple surfaces. In the Octet RED384, “Rmax
linked” was used for the group ﬁtting of data from sensors coated with the same mAb concentration,
and “Rmax unlinked by sensor” was used for the global ﬁtting of data from sensors coated with
multiple mAb concentrations. Both the multi-cycle and single-cycle kinetic data from the IBIS MX96
were analyzed using Scrubber (v.2.0c). The kd was ﬁrst determined by ﬁtting the data in the absence
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the kd. For single-cycle kinetic data, the injection start time was set as a ﬂoating parameter, and the
association proﬁles were ﬁt back to a theoretical baseline origin. In all of the analyses, ka is the
association rate constant for the antibody–antigen binding reaction, kd is the dissociation rate con-
stant for the antibody–antigen complex, and KD is the equilibrium dissociation constant deﬁned by kd/
ka. The ﬁtting accuracy was described by Chi2 (Biacore T100, ProteOn XPR36, and IBIS MX96) or X2
(Octet RED384), a parameter representing how well the observed results resemble those calculated
from the model used to analyze the data.
2.7.2. Ligand surface activity
The binding activity of surface-bound mAbs toward human PCSK9, called the % ligand activity, was
calculated using the following equations:
% Ligand Activity¼ Experimental Rmax
Theoretical Rmax
100%
where the theoretical Rmax (the binding capacity of the surface) was determined as follows:
Theoretical Rmax ¼
Analyte MW
Ligand MW
RLSM
where MW was the molecular weight of the ligand (mAb, 150 kDa) and analyte (human PCSK9,
72.8 kDa), RL (ligand response) was the amount of immobilized ligand in response units (RU), and SM
was the stoichiometry deﬁned by the number of binding sites on the ligand. Rearranging the equation
provides the calculation for the ligand density to aim for in the experiments:
RL ¼
Ligand MW
Analyte MW
Rmax 1SM
For the kinetic binding measurements, Rmax was set at 50–200 RU.Acknowledgments
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